公开(公告)号：US20130289039A1

公开(公告)日：2013-10-31

申请号：US13927439

申请日：2013-06-26

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Richard Hsia ,  H. Scott WILKINSON ,  Tushar Misra ,  Kostas Saranteas ,  Patrick Mousaw

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: A novel besylate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.

公开(公告)号：US20150203501A1

公开(公告)日：2015-07-23

申请号：US14525861

申请日：2014-10-28

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： H. Scott WILKINSON ,  Richard HSIA ,  Tushar MISRA ,  Kostas SARANTEAS ,  Patrick MOUSAW

IPC: C07D487/04 ,  C07C57/145

CPC classification number: C07D487/04 ,  C07C57/145

Abstract: A novel maleate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.

Abstract translation: （6-（5-氯-2-吡啶基）-5 - [（4-甲基-1-哌嗪基）羰氧基] -7-氧代-6,7-二氢-5H-吡咯并[3,4 -b]吡嗪）。

公开(公告)号：US20150225334A1

公开(公告)日：2015-08-13

申请号：US14692843

申请日：2015-04-22

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Craig R. ABOLIN ,  H. Scott WILKINSON ,  Paul MCGLYNN ,  William K. MCVICAR

IPC: C07C233/43 ,  A61K9/00 ,  A61K45/06 ,  A61K31/167

CPC classification number: C07C233/43 ,  A61K9/0075 ,  A61K9/008 ,  A61K31/167 ,  A61K31/4015 ,  A61K45/06 ,  C07B2200/13 ,  C07C231/18

Abstract: The compound of formula (I) is a water-stable, long acting β2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.

Abstract translation: 式（I）化合物是用作治疗与可逆性阻塞性气道疾病等相关的支气管收缩剂的支气管扩张剂的水稳定性长效β2-选择性肾上腺素受体激动剂。 公开了制备式（I）化合物以及相关中间体的方法。

公开(公告)号：US20130289040A1

公开(公告)日：2013-10-31

申请号：US13928571

申请日：2013-06-27

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： H. Scott WILKINSON ,  Richard HSIA ,  Tushar MISRA ,  Kostas Saranteas ,  Patrick MOUSAW

IPC: C07D487/04

CPC classification number: C07D487/04 ,  C07C57/145

Abstract: A novel maleate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.

公开(公告)号：US20130296565A1

公开(公告)日：2013-11-07

申请号：US13932324

申请日：2013-07-01

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： H. Scott WILKINSON ,  Richard HSIA ,  Tushar MISRA ,  Kostas SARANTEAS ,  Patrick MOUSAW

IPC: C07D487/04 ,  C07C59/245

CPC classification number: C07D487/04 ,  C07C59/245

Abstract: A novel L-malate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.

Abstract translation: （6-（5-氯-2-吡啶基）-5 - [（4-甲基-1-哌嗪基）羰氧基] -7-氧代-6,7-二氢-5H-吡咯并[3 ，4-b]吡嗪）。

公开(公告)号：US20130065904A1

公开(公告)日：2013-03-14

申请号：US13673076

申请日：2012-11-09

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Judy CARON ,  Thomas WESSEL ,  Karim LALJI ,  Mark VARNEY ,  Roger P. BAKALE ,  Surendra P. SINGH ,  H. Scott WILKINSON ,  Xiping SU ,  Zhengxu HAN ,  Stefan G. KOENIG

IPC: A61K31/4985 ,  A61P25/00 ,  A61P25/16 ,  A61P25/24 ,  A61P25/28 ,  A61P15/12 ,  A61P25/22

CPC classification number: A61K31/4985 ,  A61K31/135 ,  C07C211/42 ,  C07C2602/10 ,  A61K2300/00

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Abstract translation: 本发明的一个方面涉及含有两种或更多种活性剂的药物组合物，所述活性剂当一起用于治疗例如更年期，情绪障碍，焦虑障碍或认知障碍时。 药物组合物的第一组分是镇静剂佐佐匹克。 药物组合物的第二组分是反式4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺或反式4-（3,4-二氯苯基） 2,3,4-四氢-1-萘胺。 本发明还涉及治疗绝经，围绝经期，情绪障碍，焦虑障碍和认知障碍的方法。